Ponatinib has shown long-term responses of major cytogenic response (MCyR) or major molecular response (MMR) in patients with R/R CML or with the T315I BCR::ABL1 mutation [4, 19]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.